The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
Open Access
- 14 December 2001
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 16 (2) , 147-154
- https://doi.org/10.1096/fj.01-0552com
Abstract
Plasminogen activator inhibitor 1 (PAI-1) is believed to control proteolytic activity and cell migration during angiogenesis. We previously demonstrated in vivo that this inhibitor is necessary for o...Keywords
This publication has 32 references indexed in Scilit:
- The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not VitronectinThe Journal of cell biology, 2001
- Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast CancerThe International Journal of Biological Markers, 2000
- Regulation of cell adhesion by PAI‐1APMIS, 1999
- Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularizationNature Medicine, 1998
- uPA, uPAR, PAI-I: Key intersection of proteolytic, adhesive and chemotacfic highways?Immunology Today, 1997
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997
- The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectinNature, 1996
- Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?The Journal of cell biology, 1996
- Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.Journal of Clinical Investigation, 1995
- Histotypic angiogenesis in vitro: Light microscopic, ultrastructural, and radioautographic studiesIn Vitro Cellular & Developmental Biology - Plant, 1982